Since 2007, Tigenix is listed on the Euronext Brussels stock exchange. Now, the Leuven-based company wants to expand its reach and has announced a request for registration on the American Nasdaq stock market.
Tigenix is currently developing its product Cx601, based on adipose stem cells for the treatment of perianal fistulas. After the favorable results of its European phase 3 clinical trial, the company had mentioned that a public offering in the US was being considered to finance FDA-approved phase 3 trials in the States. However, the stem cell specialist clearly states that its search for a partner in the development and commercialization of Cx601 is still ongoing.
With this additional US stock listing, Tigenix follows the example of several other companies. Also Galapagos completed a successful IPO at Nasdaq in May of this year, while also being listed on Euronext Brussels.